Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Xoma, known for discovery and development of therapeutic antibodies, has signed an agreement with Aragen Bioscience for antibody humanization.
Subscribe to our email newsletter
Under the terms of the deal, Aragen Bioscience will provide its clients access to Xoma’s Human Engineering technology for antibody humanization.
The financial terms of the agreement have not been disclosed.
The Human Engineering technology helps derive humanized variable region amino acid sequences from mature mouse variable region amino acid sequences.
Aragen Bioscience president and CEO Rick Srigley said the company can now provide antibody testing, variable domain humanization, stable and transient expression, cell line development and pre-clinical production services to its customers.
"The addition of XOMA’s technology to our services enables our clients to quickly access antibody humanization technology that is recognized throughout the industry as cutting-edge," Srigley added.